# US 8,541,377 B2 · Optimized dengue virus entry inhibitory peptide (DN81)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,377 B2
- Document ID: US8541377B2
- Status: Granted
- Kind: B2
- Application number: 12/668,828
- Filed: 2008-07-11
- Published: 2011-05-12
- Granted: 2013-09-24
- Earliest claimed: 2007-07-13
- Assignees: Florida Gulf Coast University
- Applicants: Scott F. Michael; Sharon Isern; Robert Garry; Ram Samudrala; Joshua Costin; Ekachai Jenwitheesuk
- Inventors: Scott F. Michael; Sharon Isern; Robert Garry; Ram Samudrala; Joshua Costin; Ekachai Jenwitheesuk
- Web page: https://patentgrep.com/patent/US8541377B2

## CPC

- C07K 14/005: from viruses
- A61P 31/12: Antivirals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates peptide entry inhibitors and methods of determining such inhibitors that are bindable to regions of viruses having class II E proteins, such as the dengue virus E protein, as candidates for in vivo anti-viral compounds.

## Claims

### Claim 1

A synthetic peptide comprising: an amino acid sequence presented as SEQ ID NO: 1.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide inhibits a class II viral envelope protein.

### Claim 3 (depends on 2)

The peptide of claim 2, wherein the class II envelope protein is a dengue virus E protein.

### Claim 4 (depends on 1)

The peptide of claim 1, wherein the peptide inhibits dengue virus virion:cell fusion.

### Claim 5 (depends on 1)

A pharmaceutical composition comprising the peptide of claim 1.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, further comprising a biocompatible carrier.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the biocompatible carrier is selected from the group consisting of saline, buffered saline, dextrose and water.

### Claim 8

A method of treating dengue virus infection in a subject comprising the steps of: administering a therapeutically effective amount of the peptide comprising the amino acid sequence presented as SEQ ID NO: 1 to a subject in need thereof.

### Claim 9 (depends on 8)

The method of claim 8, wherein the peptide inhibits dengue virus virion:cell fusion.

### Claim 10 (depends on 8)

The method of claim 8, wherein the peptide is administered intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, orally or intranasally.

### Claim 11 (depends on 8)

The method of claim 8, wherein the peptide is conjugated to a carrier molecule.

### Claim 12 (depends on 11)

The method of claim 11, wherein the carrier molecule is human serum albumin (HSA).

### Claim 13 (depends on 10)

The method of claim 10, wherein the peptide is administered to a mammal.